Astellas Pharma (OTCMKTS:ALPMY) Lowered to “Hold” Rating by Zacks Research

Zacks Research lowered shares of Astellas Pharma (OTCMKTS:ALPMY) from a strong-buy rating to a hold rating in a report published on Wednesday morning,Zacks.com reports.

Separately, Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $13.09 on Wednesday. The company has a 50 day moving average of $13.51 and a 200 day moving average of $14.64. The stock has a market cap of $23.69 billion, a P/E ratio of 12.19 and a beta of 0.07. Astellas Pharma has a 12 month low of $9.91 and a 12 month high of $17.35. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. As a group, sell-side analysts forecast that Astellas Pharma will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).